Neurotech International Limited (NTI:ASX) Neurotech director liable of misconduct

Neurotech’s strategic adviser, Dr. Adrian Attard Trevisan, has been found guilty of misconduct after the Malta Times published an article suggesting he never completed a PhD in neuroscience.

Dr. Adrian Attard Trevisan has admitted to his wrong-doing, stating he mislead the public and has never completed a PhD in Neuroscience, from the University of College London. But instead, Dr. Attard Trevisan has a completed PhD in Human Physiology from the University of Milan.

As a result, Dr. Adrian Attard Trevisan has resigned, as the director of Neutrotech Limited, in June 2018 and no longer has any involvment with the company and its board or management team.

“Neurotech’s flagship product Mente is the result of much more than the work of one person. Neurotech’s dedicated Mente team has worked for many years to create, refine and improve the device and its therapeutic outcomes – and that work continues today, and into the future,” Neurotech International Limited.

Please find announcement attached: https://hotcopper.com.au/documentembed?id=uOMxKKzFkiWRTLKhOROKAxjvTDYD4Qq0yhKZruNwke92GA%3D%3D

Fri, 17 May	Close	Change
4:49pm	7,814.4	66.9
Closed at Sun, 19 May 8:38pm

S&P/ASX Sm. Ords.	3,043.6	31.7	1.03%
All Ordinaries	8,082.3	67.8	0.83%
S&P/ASX 100	6,562.8	53.1	0.80%

NC6	NANOLLOSE LIMITED	3.2¢	39.1%
WNX	WELLNEX LIFE LIMITED	2.9¢	38.1%
LPE	LOCALITY PLANNING ENERGY HOLDINGS LIMITED	11.0¢	29.4%

MSI	MULTISTACK INTERNATIONAL LIMITED	0.9¢	30.8%
8VI	8VI HOLDINGS LIMITED	4.5¢	25.0%
MKT	THE MARKET LIMITED	17.0¢	15.0%

Neurotech director liable of misconduct

Health Care, The Market Herald

NTI by the numbers

This stock provides Oz’s only HIV self-test kit – and it’s bullish on the budget

Recce Pharma heading closer to full efficacy data for flagship R327

Breaking barriers in cancer treatment: Race Oncology pioneers a new era with bisantrene

Optiscan agreement with Mayo Clinic aims to expedite robotic surgery